deltatrials
Completed PHASE1 NCT00003395

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm
Interventions arsenic trioxide
Updated 5 times since 2017 Last updated: Jun 24, 2013 Started: Apr 30, 1998 Primary completion: Mar 31, 2000 Completion: Mar 31, 2000

Listed as NCT00003395, this PHASE1 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Apr 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States